Lung Cancer

Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.

Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer.

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.

Pembrolizumab plus olaparib as first-line maintenance therapy did not improve survival in patients with metastatic nonsquamous non–small cell lung cancer.

Becotarug plus osimertinib elicited responses with manageable safety in patients with non–small cell lung cancer and EGFR exon 12 insertion mutations.

Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC.

Perioperative nivolumab improved responses in resectable non–small cell lung cancer, irrespective of the number of neoadjuvant treatment cycles completed.

Stereotactic ablative radiotherapy has shown clinical benefit in combination with immunotherapy in early-stage NSCLC, making it a viable treatment to consider.

Charles B. Simone II, MD, FASTRO, FACRO, discusses advanced radiation techniques that could reduce cardiac toxicities.

Vlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation.

Raj Singh, MD, discusses radiation therapy in patients with metastatic lung cancer, highlighting the evolution of treatment within this landscape.

Paul D. Brown, MD, gives a history of prophylactic cranial irradiation in small cell lung cancer and describes its standing in the treatment paradigm.

A study sheds light on how immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening.

Bruna Pellini, MD, discusses the utility of circulating tumor DNA assays in non–small cell lung cancer.

Federico Cappuzzo, MD, discusses the clinical significance of the RATIONALE-315 trial of perioperative tislelizumab in non–small cell lung cancer.

The FDA has accepted a new drug application for ensartinib in metastatic ALK-positive non–small cell lung cancer.

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

Benjamin Levy, MD, explores the potential role of antibody-drug conjugates in non–small cell lung cancer.

Neel P. Chudgar, MD, discusses the nuances of defining resectability in patients with non–small cell lung cancer.

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

China’s National Medical Products Administration has accepted the second NDA for first-line taletrectinib for ROS1-positive non–small cell lung cancer.

Benjamin Philip Levy, MD, discusses lingering questions regarding the use of antibody-drug conjugates in lung cancer.

The partial clinical hold placed on the phase 2 IOV-LUN-202 trial of LN-145 in non–small cell lung cancer has been lifted by the FDA.

MAAs for datopotamab deruxtecan in non–small cell lung cancer and hormone receptor–positive, HER2-negative breast cancer have been validated by the EMA.